About
Experts
Webinars & Conferences
Webinars
Conference recordings
External Webinars
Antimicrobial Viewpoints
Resources
Library
Antimicrobial Encyclopaedia
Conference calendar
JOIN US
Log in
Lost your password?
Create your account
My account
Logout
You are here
:
Home
-
Preclinical development
Advanced search
Search our library
Use the filters below to narrow your search:
Content format
Article
Definition
Encyclopaedia
External resource
Video
Resource type
Antimicrobial Viewpoint
Conference
Database
Funding Mechanism
Guideline
Organization
Presentation
Project
Protocol/SOP
Publication
Scientific Journal
Tool
Video
Webinar
Drug development
CMC
Discovery
Exploratory
Hit-to-lead
Lead-to-candidate
Phase 1
Phase 2
Phase 3
Phase 4
PK/PD
Preclinical development
Regulatory
Screening
Toxicology
Indication
ABSSI
Bloodstream infection
Gonorrhoea
HAP/VAP
IAI
Pneumonia
SSTI
STI
Tuberculosis
UTI
Microbe / Microbial properties
Acinetobacter baumannii
Enterobacteriaceae
Enterococcus faecium
Escherichia coli
ESKAPE
Gram negative
Gram positive
Klebsiella pneumoniae
MDR
PDR
Pseudomonas aeruginosa
Staphylococcus aureus
WHO priority pathogens
XDR
Antibiotics class
Aminoglycosides
Carbapenems
Cephalosporins
Diarylquinolines
Glycopeptides
Lincomycins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Other tags
Access
Diagnostics
Stewardship
Search
European Gram Negative AntiBacterial Engine (ENABLE)
European Commission: Funding opportunities
NIAID: Opportunities & Announcements
REPAIR Impact Fund
CARB-X
Drug Development Process
Tackling the drug-resistance pandemic – 2020 and beyond
Why we need to prioritize developing antibiotics for children
Bringing antimicrobial research and development to Africa – the time is now
The REPAIR Impact Fund: Reflections from the first year
Time to pull out all the stops in the fight against superbugs
Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
Building better breakpoints: data and methods needed to determine breakpoints for new agents
Exploring safety issues in antimicrobial drug development
Moving from preclinical to clinical-stage: Challenges and opportunities
Clinical development of antimicrobials – Phase 1 development challenges
Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
Probability of target attainment analyses for dose selection in antimicrobial drug development
PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
Non-traditional antibacterial therapeutic options and challenges
Testing for the potential of emergence of antimicrobial resistance
Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
Models for antimicrobial R&D: Computational modelling for population PK and PKPD
Enabling academia to fill the discovery gap – Learnings from industry and funders
Infection models for antimicrobial R&D: Intracellular models
Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research
NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
Minimum inhibitory concentration (MIC)
Maximum tolerated dose (MTD)
Investigational new drug (IND)
Epidemiological cut-off value (ECOFF)
Pharmacokinetics-pharmacodynamics (PK/PD)
Tissue concentration
Intracellular concentration
Preclinical development
Median effective dose (ED50)
Toxicity
Target product profile (TPP)
Target candidate profile (TCP)
Pro-drug
Median lethal dose (LD50)
Mechanism of action (MoA)
Cmax
Absorption, distribution, metabolism, elimination (ADME)
Antimicrobial susceptibility testing (AST), resistance testing
PK/PD
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Candidate
Active pharmaceutical ingredient (API)
AntibioticDB
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our
cookie policy